I’m sorry, what? I’m re-reading the title.

Laguna’s approach uses attenuated Listeria monocytogenes.

For those wondering – YES, this the same bacterium that gives you food poisoning from undercooked deli meats. Laguna is engineering it into a drug for pediatric leukemia patients.

Yeah, you read that correctly. And the FDA cleared it.

So, in all reality, a live bacteria-based cancer therapy isn’t crazy. Like, at all.

There is an entire sub-segment of the industry doing this.

Laguna Biotherapeutics announced FDA IND clearance for LGNA-100, a first-in-class live bacterial immunotherapy.

The asset is built on Laguna’s QUAIL platform, a pipeline of highly attenuated Listeria strains engineered to activate and expand γδ T cells and MAIT cells, two underused arms of the innate immune system.

The Phase 1 trial will evaluate LGNA-100 in pediatric and young adult patients with high-risk AML, ALL, and MDS following αβ-depleted hematopoietic stem cell transplantation.

The objective is preventing post-transplant relapse by switching on innate immune surveillance the patient’s own cells should be doing.

This is pretty clever but not unheard of. Basically, you throw a bunch of bacteria in there to make the innate immune system “freak out”. In the ensuing freakout, the innate immune cells kill the bacteria AND the cancer cells.

Before you write this off as a science-fair experiment, look at the founders. Dan Portnoy is one of them.

THE Dan Portnoy.

The UC Berkeley microbiologist whose lab has spent thirty years building the foundational understanding of how Listeria evades the immune system, escapes the phagosome, and activates cytosolic immunity.

The entire field of Listeria-based cancer therapeutics traces its biology back to his bench.

He co-founded Laguna with Jonathan Kotula, who serves as CEO, and Russell Carrington. The company is headquartered in San Francisco with research labs in Siena, Italy.

The trial design is shrewd.

Post-HSCT pediatric leukemia is a population with terrible outcomes when relapse happens, and a clear unmet need. αβ T cell-depleted transplants leave γδ T cells largely intact, which gives LGNA-100 a population to expand.

If the drug shows immune signal without sepsis-like toxicity, the regulatory and ethical framing improves dramatically. Pediatric oncology has been one of the more receptive areas to genuinely novel modalities, partly because the alternatives are so grim.

The pipeline beyond LGNA-100 includes AML, other high-risk leukemias, and soft-tissue sarcomas. The QUAIL platform is described as a pipeline of multiple attenuated Listeria strains, suggesting Laguna sees this as a category, not a one-asset bet.

The honest read: this could fail loudly in Phase 1 if dose-limiting toxicity emerges, or it could be the first credible win for live bacterial immunotherapy since Coley’s toxins.

Either way, it’s one of the most scientifically distinctive IND clearance you’ll read about this week.